These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21474480)

  • 1. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient.
    Luque S; Grau S; Valle M; Colino CI; Ferrer A
    J Antimicrob Chemother; 2011 Jul; 66(7):1653-4. PubMed ID: 21474480
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.
    Cook AM; Martin C; Adams VR; Morehead RS
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3240-3. PubMed ID: 21576432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
    Myzienski AE; Lutz MF; Smythe MA
    Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of multiple-dose levofloxacin in hemodialysis patients.
    Tsuruoka S; Yokota N; Hayasaka T; Saito T; Yamagata K
    Am J Kidney Dis; 2011 Sep; 58(3):498-9. PubMed ID: 21715074
    [No Abstract]   [Full Text] [Related]  

  • 5. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients.
    Riney JN; Hollands JM; Smith JR; Deal EN
    Ann Pharmacother; 2010; 44(7-8):1141-51. PubMed ID: 20587743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition kinetics, urinary excretion and dosage regimen of levofloxacin formulation following single intravenous administration in crossbred calves.
    Dumka VK; Srivastava AK
    Vet Res Commun; 2007 Oct; 31(7):873-9. PubMed ID: 17279462
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
    Albarellos GA; Ambros LA; Landoni MF
    J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
    Pai MP; Mercier RC; Allen SE
    Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
    Benko R; Matuz M; Doro P; Peto Z; Molnar A; Hajdu E; Nagy E; Gardi J; Soos G
    Int J Antimicrob Agents; 2007 Aug; 30(2):162-8. PubMed ID: 17570646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ofloxacin in broiler chicken.
    Kalaiselvi L; Sriranjani D; Ramesh S; Sriram P; Mathuram LN
    J Vet Pharmacol Ther; 2006 Jun; 29(3):185-9. PubMed ID: 16669862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended antibiotic prophylaxis for prevention of surgical-site infections in morbidly obese women who undergo combined hysterectomy and medically indicated panniculectomy: a cohort study.
    El-Nashar SA; Diehl CL; Swanson CL; Thompson RL; Cliby WA; Famuyide AO; Stanhope CR
    Am J Obstet Gynecol; 2010 Mar; 202(3):306.e1-9. PubMed ID: 20207249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of levofloxacin in male camels (Camelus dromedarius).
    Goudah A
    J Vet Pharmacol Ther; 2009 Jun; 32(3):296-9. PubMed ID: 19646095
    [No Abstract]   [Full Text] [Related]  

  • 14. Research review and update: IQUIX (levofloxacin 1.5%).
    McDonald MB
    Int Ophthalmol Clin; 2006; 46(4):47-60. PubMed ID: 17060791
    [No Abstract]   [Full Text] [Related]  

  • 15. Levofloxacin pharmacokinetics in children.
    Chien S; Wells TG; Blumer JL; Kearns GL; Bradley JS; Bocchini JA; Natarajan J; Maldonado S; Noel GJ
    J Clin Pharmacol; 2005 Feb; 45(2):153-60. PubMed ID: 15647407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, urinary excretion and milk penetration of levofloxacin in lactating goats.
    Goudah A; Abo-El-Sooud K
    J Vet Pharmacol Ther; 2009 Feb; 32(1):101-4. PubMed ID: 19161462
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous ciprofloxacin dosing in a morbidly obese patient.
    Caldwell JB; Nilsen AK
    Ann Pharmacother; 1994 Jun; 28(6):806. PubMed ID: 7919576
    [No Abstract]   [Full Text] [Related]  

  • 18. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
    Deguchi T; Nakane K; Yasuda M; Shimizu T; Monden K; Arakawa S; Matsumoto T
    Int J Antimicrob Agents; 2010 Jun; 35(6):573-7. PubMed ID: 20226636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific antibodies, levofloxacin, and modulation of capsule-associated virulence in Streptococcus pneumoniae.
    Tarragó D; Lara N; Fenoll A; Casal J; Giménez MJ; Aguilar L; Sevillano D
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3095-6. PubMed ID: 15980409
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of intravenously administered levofloxacin in men and women.
    Overholser BR; Kays MB; Lagvankar S; Goldman M; Mueller BA; Sowinski KM
    Pharmacotherapy; 2005 Oct; 25(10):1310-8. PubMed ID: 16185174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.